An Update on Emerging S1P Therapeutics for the Management of Patients With Relapsing Multiple Sclerosis

This CME program will highlight data presented at the 7th Annual Joint ECTRIMS – ACTRIMS Meeting in Paris, France. The three expert faculty will analyze recent therapeutic advances in the treatment and management of multiple sclerosis (MS). The clinical relevance of emerging and emerged trial data, particularly regarding S1P therapeutics, will be assessed. Faculty will outline strategies for utilizing the multidisciplinary team approach to develop and implement data-driven, tailored treatment plans in clinical practice. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of MS in order to improve outcomes and quality of care.


This activity has been designed to meet the educational needs of cardiologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.


Upon completion of this activity, participants will be better able to do the following:

  1. Analyze the most recent clinical trial data of S1P therapeutics for the management of patients with relapsing multiple sclerosis presented at the joint ECTRIMS-ACTRIMS Meeting.
  2. Apply data-driven treatment strategies to reduce relapse rates and improve outcomes for patients with relapsing multiple sclerosis


Joseph R. Berger, MD
Professor of Neurology and MS Division Co-Chief
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Suhayl Dhib-Jalbut, MD
Chairman, Department of Neurology
Professor of Neurology
Rutgers University
New Brunswick, New Jersey

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:

Joseph R. Berger, MD

Consultant/Advisor: Alkermes; Amgen Inc.; AstraZeneca; Bayer AG; Biogen; Excision BioTherapeutics; Genentech, Inc.; Inhibikase Therapeutics, Inc.; Novartis AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited

Grant/Research Support: Biogen; Teva Pharmaceuticals USA

Suhayl Dhib-Jalbut, MD

Consultant/Advisor: Actelion Pharmaceuticals US, Inc; Genzyme Corporation; Teva Pharmaceuticals USA

Grant/Research Support: Biogen; Teva Pharmaceuticals USA

Fred D. Lublin, MD

Consultant/Advisor: AbbVie Inc.; Acorda; Actelion Pharmaceuticals US, Inc; Akros Pharma Inc.; Atara Biotherapeutics; Bayer AG; Biogen; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc; Genzyme Corporation; Innate Immunotherapeutics Limited; Mapi-Pharma Ltd; Medday; MedImmune; Novartis AG; Polypharma, Inc.; Receptos; Regeneron; F. Hoffmann-La Roche Ltd; sanofi-aventis U.S. LLC; Teva Pharmaceuticals USA; TG Therapeutics, Inc.; Toyama

Grant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; National Institutes of Health; National MS Society; Novartis AG; sanofi-aventis U.S. LLC; Teva Pharmaceuticals USA; Transparency Life Sciences

Speakers Bureau: Genentech, Inc.; Genzyme Corporation

Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Boring and Nicole Brestowski hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This CME activity has been supported by an independent educational grant from Celgene Corporation and Mallinckrodt Pharmaceuticals, Inc.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME, Celgene Corporation and Mallinckrodt Pharmaceuticals, inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
Course expires: 
Please login or register to take this course.